CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice

AIM: There is limited information concerning the effects of canagliflozin (CANA), a sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) in a real‐world clinical setting in Canada. CanCARE is a 12‐month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual c...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Vincent, Bell, Alan, Clement, Maureen, Noronha, Luis, Tsoukas, Michael A., Camacho, Fernando, Traina, Shana, Georgijev, Natasha, Culham, Matthew D., Rose, Jennifer B., Rapattoni, Wally, Bajaj, Harpreet S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667918/
https://www.ncbi.nlm.nih.gov/pubmed/30393961
http://dx.doi.org/10.1111/dom.13573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667918/
https://www.ncbi.nlm.nih.gov/pubmed/30393961
http://dx.doi.org/10.1111/dom.13573

Ejemplares similares